China's Next-Generation Industrial Policy: Implications for Biotechnology and Biomedicine

A decade after Made in China 2025, Beijing is widening state intervention across supply chains and frontier technologies — and biomedicine remains one of the few advanced sectors where the technological gap has not closed.

---

Executive Summary

China's industrial strategy is entering a new phase. A Rhodium Group assessment prepared for the U.S. Chamber of Commerce concludes that state intervention is becoming more systemic and pervasive, extending across all layers of production — from upstream inputs and industrial equipment to downstream applications, services, and frontier technologies — rather than concentrating on a defined list of strategic emerging industries.

For the biotechnology and biopharmaceutical sectors, three findings carry particular weight. First, drug development is explicitly identified as one of the service sectors receiving increased policy attention, alongside software and data processing. Second, biomedicine is named among the areas where Chinese firms have not yet closed the technological gap, alongside high-end semiconductors and advanced aerospace. Third, artificial intelligence has become a central pillar of industrial policy, with public procurement and state-owned enterprises used to generate demand and accelerate adoption at scale.

The assessment also documents significant internal strain. Growth is slowing, domestic demand is weak, fiscal pressures are rising, and capital allocation efficiency is declining. Beijing's response has been to recentralize and tighten coordination of financial resources rather than to scale back intervention. Externally, the combination of sustained policy support and weak domestic demand has driven a rapid expansion of China's manufacturing trade surplus, which the report states has roughly doubled since 2019 to around $2 trillion.

The evidence base here is policy and industry analysis, not peer-reviewed experimental science. Its value lies in documenting the direction and instruments of state strategy; its limitation lies in the difficulty of attributing sector-level biomedical outcomes to policy design rather than to market dynamics, talent flows, or global research collaboration.

---

Introduction

Industrial policy has returned as a central instrument of economic statecraft, and no major economy has pursued it with more breadth than China. The question for biotechnology and life sciences is no longer whether China's industrial strategy matters to the sector, but how it now operates, where it is succeeding, and where it remains constrained.

That question has a documented history. In late 2015, the U.S. Chamber of Commerce translated the foundational planning document — commonly referred to as the "Green Book" — that set out the localization targets and strategic roadmap underpinning Made in China 2025. Independent assessments followed from the Mercator Institute for China Studies in 2016, the European Union Chamber of Commerce in China in 2017, and the U.S. Chamber of Commerce in 2017. All three reached broadly consistent conclusions about the competitive implications of state-directed industrial upgrading.

A decade later, the Rhodium Group assessment finds that outcomes tracked the original ambitions to a striking degree in many sectors, while identifying persistent vulnerabilities in the most technologically demanding areas — including biomedicine. The analysis that follows examines what that record implies for biotechnology research, drug development, biomanufacturing, clinical research, and the global distribution of biomedical innovation capacity.

---

Scientific and Policy Background

Made in China 2025 was a targeted program. It identified a defined set of strategic emerging industries, established localization targets for domestic content, and directed state resources toward building domestic capabilities in advanced manufacturing. The policy architecture assumed that concentrated intervention in selected sectors could compress the time required to close technological gaps with established industrial economies.

The current framework operates differently. According to the assessment, Chinese leadership views past policies as largely successful in building domestic capabilities and global competitiveness, even while identifying areas for improved execution and remaining keenly aware of persistent dependencies in high-tech inputs. Rather than narrowing focus, the next phase extends support across mature sectors, foundational supply chain nodes, and frontier technologies simultaneously.

Several structural features define this approach:

Mature sectors are not abandoned. Even in industries facing overcapacity and severe price pressure, Beijing is providing continued support and pushing firms to upgrade production technologies to gain market share and lower costs, rather than cutting capacity.
Upstream control is being extended. In segments including critical minerals, wafers, and magnets, China already holds dominant positions, and policymakers are seeking to replicate that position across a broader range of industrial products.
Services are receiving more attention. Software, data processing, and drug development — relatively neglected in earlier rounds — are now visible priorities.
Frontier technologies are treated as commercialization targets. Artificial intelligence, quantum technologies, and future energy systems are no longer framed solely as R&D priorities; public procurement and state-owned enterprise demand are being used to drive adoption at scale.

The biomedical relevance of these categories is not uniform. Biopharmaceutical research depends on talent density, regulatory predictability, clinical infrastructure, and access to global scientific networks to a greater degree than on upstream mineral or equipment control. That distinction matters when translating industrial policy analysis into expectations for life sciences outcomes.

---

Research Findings

The assessment's central findings can be organized into four areas, each with distinct implications for biotechnology.

1. From targeted intervention to systemic intervention. The report describes a shift from sectoral industrial policy to what it characterizes as an "industrial policy of everything." Support now extends across all layers of production, encompassing mature industries, foundational supply chain nodes, and frontier technologies. The practical effect is that foreign dependence on Chinese supply chains can deepen even in sectors that are not themselves the nominal target of policy.

2. Refined instruments under tighter macroeconomic constraints. China faces slowing growth, weak domestic demand, rising fiscal pressures, and declining efficiency of capital allocation. Rather than reducing intervention, authorities are recentralizing financial coordination. Government guidance funds are being consolidated and aligned more closely with national objectives; bank lending is increasingly steered through targeted relending facilities and regulatory guidance; and wasteful or redundant tax and fiscal subsidies — especially at the local level — are being culled. The report notes that these changes may prolong the potency of industrial policy while carrying long-term ramifications for overall economic efficiency.

3. Rising internal strain. The expansion of industrial policy across an ever-wider set of sectors risks diluting its effectiveness. Evidence of strain is already visible in declining corporate profitability, weakening private investment, and slowing R&D growth in key sectors. Over time, the report suggests, these dynamics could weigh on productivity and long-term growth potential even as they support short-term industrial gains.

4. Accelerating global impact. Sustained policy support combined with weak domestic demand has driven a rapid expansion of China's manufacturing trade surplus, which the report states has roughly doubled since 2019 to approximately $2 trillion. This reflects both rising exports and successful import substitution. Some observers describe the phenomenon as a "China Shock 2.0." Beijing is also increasingly deploying policy tools intended to entrench its position in global value chains and to counter foreign diversification strategies.

Within this broad picture, the biomedical sector occupies an unusual position. It is explicitly listed among the areas where Chinese firms have not yet closed the technological gap — a group that also includes high-end semiconductors and advanced aerospace. At the same time, drug development appears among the service activities receiving heightened policy attention. These two findings are not contradictory; they describe a sector where state ambition is rising faster than demonstrated capability at the frontier.

---

Industry Impact

The implications for the biotechnology industry, pharmaceutical development, and global health infrastructure differ by segment.

Manufacturing and supply chains. Biomanufacturing depends on upstream inputs that include specialty chemicals, single-use systems, chromatography resins, reagents, and precision equipment. To the extent that China's next-generation policy extends support into foundational supply chain nodes, global biopharmaceutical manufacturers may face a narrower field of qualified non-Chinese suppliers in specific categories. The report's framing suggests that foreign diversification strategies will encounter increasingly deliberate countermeasures, which raises the cost and complexity of supply chain redundancy planning.

Pharmaceutical development. The identification of drug development as a service sector receiving policy attention is significant for a different reason. Drug development is a knowledge-intensive activity in which outcomes depend heavily on clinical infrastructure, regulatory pathways, and integration with international research networks. Policy support can accelerate capacity expansion — in discovery services, contract research, and clinical trial execution — but does not by itself resolve gaps in frontier therapeutic capability.

Clinical research. Multinational trial sponsors have increasingly looked to Chinese sites for patient recruitment and cost efficiency. A more coordinated state approach to the life sciences service sector could deepen that integration, while simultaneously increasing geopolitical scrutiny of data governance, trial transparency, and cross-border research collaboration.

Investment and collaboration. The consolidation of government guidance funds and the redirection of bank lending toward national priorities affect the capital available to private biotechnology ventures, both domestic and foreign-linked. The report notes weakening private investment as a visible sign of strain. For international venture capital and pharmaceutical partnering teams, this implies a more selective and more policy-aligned investment environment in China, with correspondingly higher diligence requirements around state-linked co-investors and technology transfer obligations.

Regulatory agencies and global health. Greater state involvement in commercializing frontier technologies raises questions about the standards applied to product approval, data integrity, and post-market surveillance. Regulatory convergence between Chinese authorities and agencies such as the FDA and EMA has improved over the past decade, but the assessment's emphasis on demand creation through public procurement and state-owned enterprises introduces a channel through which adoption decisions may be shaped by non-clinical considerations.

Long-term competitiveness. The most consequential question is whether China's biomedical sector follows the trajectory of new energy vehicles and information and communications equipment, where competitive positions were built at scale, or whether it remains in the category of persistent technological gap. The report does not resolve this, and current evidence does not support a confident forecast in either direction.

---

Clinical & Regulatory Perspective

Evidence quality must be assessed with care. The primary source for this analysis is an industry-commissioned policy assessment prepared by an independent research firm for a national chamber of commerce. It is analytical and documentary in nature, drawing on planning documents, trade data, and policy observation. It is not peer-reviewed experimental research, and it does not supply clinical endpoints, safety data, or patient outcomes.

Consequently, claims about biomedical capability should be read at the level of industrial capacity rather than therapeutic readiness. Statements that China has or has not closed a technological gap describe aggregate capability, not the safety or efficacy of any specific product.

Several regulatory considerations follow from the report's findings:

Regulatory status. Chinese authorities have progressively aligned domestic drug review pathways with international norms, but the pace and predictability of approval decisions remain relevant to multinational development planning.
Safety and data governance. Expanded state involvement in commercialization introduces questions about the independence of post-market surveillance and the handling of clinical data used in multinational submissions.
Adoption dynamics. Public procurement and state-owned enterprise demand can accelerate uptake of new technologies. This is an effective commercialization lever, but it may reduce the weight of comparative clinical evidence in adoption decisions relative to policy alignment.
Ethical considerations. Industrial policy targeting frontier biomedical technologies intersects with longstanding bioethics debates concerning human genomic data, germline intervention, and dual-use research. These are governance questions that industrial policy frameworks do not resolve on their own.
Areas requiring additional research. Sector-specific evidence remains thin. Independent, quantitative assessments of Chinese biopharmaceutical R&D productivity, clinical trial data quality, and biomanufacturing input concentration would materially improve the ability of industry and regulators to plan.

---

Future Outlook

Over the next five to fifteen years, several developments appear plausible based on the trajectory documented in the assessment, though each carries substantial uncertainty.

Artificial intelligence in biotechnology. AI is described as a central pillar of China's industrial policy, with public procurement and state-owned enterprises used to generate demand and adoption at scale. Applied to drug discovery, protein engineering, and clinical data analysis, this approach could accelerate capability building in computational biology and bioinformatics — provided that data quality, validation standards, and reproducible benchmarking keep pace with deployment.

Biomanufacturing capacity. Continued support for mature-sector upgrading suggests incremental expansion of fermentation, cell culture, and synthetic biology manufacturing capacity. Whether that capacity translates into competitive advantage in higher-value biologics, cell therapies, and gene therapies depends on process know-how and quality systems rather than on capital investment alone.

Drug discovery and clinical research. The policy emphasis on drug development as a service sector points toward continued growth in contract research, discovery services, and clinical trial execution. This may deepen global integration even as geopolitical friction increases, producing a somewhat paradoxical outcome: closer operational ties alongside tighter scrutiny.

Precision medicine and genomics. Population-scale genomics programs and precision medicine initiatives are areas where state coordination can be genuinely advantageous, given the large cohorts required. The governance of resulting genomic data, and its availability to international research collaborations, will remain a central unresolved question.

Investment and competitiveness. The report's documentation of declining corporate profitability, weakening private investment, and slowing R&D growth in key sectors suggests that the sustainability of the current approach is not assured. If fiscal constraints bind more tightly, the breadth of industrial policy may prove harder to maintain than its initial design implies.

A reasonable planning assumption for biotechnology organizations is neither convergence nor decoupling, but continued selective interdependence, with supply chain concentration risk in upstream inputs and persistent friction around data, intellectual property, and market access.

---

Conclusion

China's next-generation industrial policy represents a deliberate widening of state ambition rather than a retreat, extending across mature industries, foundational supply chains, services, and frontier technologies. For biotechnology and biomedicine, the most important findings are the explicit attention to drug development as a service sector, the use of AI and public procurement as commercialization instruments, and the acknowledgment that biomedicine remains among the sectors where the technological gap has not closed.

The evidence supporting these conclusions is documentary and analytical rather than experimental. It supports confident statements about policy direction and instrument design; it does not support confident forecasts about therapeutic capability. That distinction should guide how industry, investors, regulators, and researchers interpret the current phase — as a shift in competitive structure that is real, measurable, and uneven in its biomedical consequences.

---

Key Takeaways

China's industrial policy has shifted from targeted sectoral programs toward systemic intervention across supply chains, services, and frontier technologies, according to a Rhodium Group assessment prepared for the U.S. Chamber of Commerce.
Biomedicine is explicitly identified as an area where Chinese firms have not yet closed the technological gap, alongside high-end semiconductors and advanced aerospace.
Drug development is named among the service sectors receiving increased policy attention, alongside software and data processing.
Artificial intelligence is a central policy pillar, with public procurement and state-owned enterprises used to generate demand and accelerate adoption.
China's manufacturing trade surplus has roughly doubled since 2019 to approximately $2 trillion, a dynamic some observers describe as "China Shock 2.0."
Internal strain is documented: slowing growth, weak domestic demand, rising fiscal pressure, consolidating government guidance funds, declining corporate profitability, and weakening private investment.
The core source is industry-commissioned policy analysis, not peer-reviewed research; conclusions about biomedical capability should be read as industrial capacity assessments rather than therapeutic evidence.
Planning assumption for biotechnology organizations: selective interdependence rather than full convergence or decoupling.

---

SEO Keywords

Biotechnology, Life Sciences, Precision Medicine, Genomics, Synthetic Biology, Drug Discovery, Gene Editing, Biopharmaceutical, Clinical Research, Medical Technology, Bioinformatics, Healthcare Innovation, Artificial Intelligence, Digital Health, Biomanufacturing, Biotechnology Industry, Healthcare Research, Biomedical Innovation, Future Medicine, Scientific Research, Industrial Policy, Supply Chain, Clinical Trials

---

Suggested URL Slug

china-industrial-policy-biotech-biomedicine

---

Sources

Boullenois, C., Black, M., and Caruso, A. China's Next-Generation Industrial Policy. Rhodium Group, prepared for the U.S. Chamber of Commerce. https://rhg.com/research/chinas-next-generation-industrial-policy
U.S. Chamber of Commerce. Was Made in China 2025 Successful? Independent assessment prepared by Rhodium Group, May 2025. https://www.uschamber.com/international/report-was-made-in-china-2025-successful
Mercator Institute for China Studies (MERICS), 2016 assessment of Made in China 2025, as cited in the Rhodium Group report.
European Union Chamber of Commerce in China, 2017 assessment, as cited in the Rhodium Group report.
U.S. Chamber of Commerce, 2017 assessment, as cited in the Rhodium Group report.